Amy D Klion
National Institute of Allergy and Infectious Diseases (NIAID)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
11
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
1 more share only the name and are not shown
Trial papers
25
PubMed author-name match
Trials
Studies that name Amy D Klion as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:17 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06871579 · Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter PyloriNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Helicobacter Pylori · principal investigator
- Ph2NCT06477653 · Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Hypereosinophilic Syndrome · principal investigator
- Ph4NCT02734186 · Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With SchistosomiasisNational Institute of Allergy and Infectious Diseases (NIAID) · withdrawn · Schistosomiasis · principal investigator
- Ph2/Ph3NCT02130882 · Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeNational Institute of Allergy and Infectious Diseases (NIAID) · unknown · Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases · principal investigator
- Ph2NCT02101138 · Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeNational Institute of Allergy and Infectious Diseases (NIAID) · unknown · Hypereosinophilic Syndrome · principal investigator
- Ph4NCT01593722 · Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in LoiasisNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Loiasis · principal investigator
- Ph2NCT01111305 · Reslizumab to Prevent Post-treatment Eosinophilia in LoiasisNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Loiasis · principal investigator
- N/ANCT00091871 · A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Eosinophilia, Hypereosinophilic Syndrome · principal investigator
- N/ANCT00090662 · Collection of Data and Samples From Healthy Donors for Use in Translational ResearchNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Healthy Volunteer · principal investigator
- Ph2NCT00044304 · Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeNational Institute of Allergy and Infectious Diseases (NIAID) · active not recruiting · Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome · principal investigator
- N/ANCT00001406 · Activation and Function of Eosinophils in Conditions With Blood or Tissue EosinophiliaNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Immune System Diseases, Eosinophilia, Helminthiasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Environmental Determinants and Non-Invasive Diagnosis of Eosinophilic EsophagitisZIAAI001414 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · fiscal years 2025 · $247,568 awarded in 2025Same name and institution; not confirmed by an ID
- Eosinophils and Eosinophil Activation in the Pathogenesis of Human DiseaseZIAAI001130 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · fiscal years 2010 to 2025 · $1,980,543 awarded in 2025Same name and institution; not confirmed by an ID
- Role of Eosinophils in Spontaneous Coronary Artery Disease PathogenesisZIAAI001397 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · fiscal years 2025 · $247,568 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:17 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Treatment of patients with the hypereosinophilic syndrome with mepolizumab.N Engl J Med · 2008468 citationsRCR 11.3
- Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.N Engl J Med · 2020235 citationsRCR 12.1
- Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.N Engl J Med · 2019181 citationsRCR 8.5
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.J Allergy Clin Immunol · 2020179 citationsRCR 10.1
- Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.J Allergy Clin Immunol · 2013146 citationsRCR 4.8
- The relationship between serum IgE and surface levels of FcepsilonR on human leukocytes in various diseases: correlation of expression with FcepsilonRI on basophils but not on monocytes or eosinophils.J Allergy Clin Immunol · 200095 citationsRCR 2.0
- A randomized trial of doxycycline for Mansonella perstans infection.N Engl J Med · 200989 citationsRCR 2.5
- 88 citationsRCR 2.2
- Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.J Infect Dis · 199388 citationsRCR 3.5
- Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.J Allergy Clin Immunol Pract · 201879 citationsRCR 3.4